On the other hand, the expression of DCN in fibroblasts from scleroderma and other fibrotic diseases should be studied to clarify the mechanism of DCN in fibrosis development and to evaluate the antifibrotic efficacy of DCN–based therapies, including DCN-engineered ADSCs, DCN and their analogs, as well as DCN gene therapy. This evidence concerns the gene DCN and scleroderma.